Contineum Therapeutics, Inc Class A Common Stock

Yahoo Finance • 9 days ago

Contineum Therapeutics Reports Positive Topline Data From PIPE-791 Phase 1b PET Trial

(RTTNews) - Contineum Therapeutics, Inc. (CTNM) on Thursday announced positive topline data from its PIPE-791 Phase 1b positron emission tomography (PET) trial, which met its primary endpoint. The Phase 1b study was designed to assess the... Full story

Yahoo Finance • 2 months ago

Contineum Therapeutics Non-GAAP EPS of -$0.62

* Contineum Therapeutics press release [https://seekingalpha.com/pr/20190078-contineum-therapeutics-reports-second-quarter-2025-financial-results-updates-key-clinical] (NASDAQ:CTNM [https://seekingalpha.com/symbol/CTNM]): Q2 Non-GAAP EPS... Full story

Yahoo Finance • 3 months ago

Contineum completes enrollment in Phase 1b PET trial cohorts

SAN DIEGO - Contineum Therapeutics (NASDAQ:CTNM), a clinical-stage biotech currently trading at $4.53 and according to InvestingPro analysis showing signs of being overvalued, has completed enrollment of healthy volunteer and progressive m... Full story

Yahoo Finance • 3 months ago

ArrePath Announces Closing of Their Next Financing Round and Appointment of a New Board Chair

PRINCETON, N.J.--(BUSINESS WIRE)--ArrePath, a company applying its proprietary artificial intelligence and machine learning platform together with deep R&D technical expertise to address the challenge of best-in-class antibacterial drug di... Full story